Clinical Trials Logo

Clinical Trial Summary

Ventilation heterogeneity is a hallmark feature of most obstructive pulmonary diseases. In particular, chronic obstructive pulmonary disease (COPD) is pathologically and physiologically characterized by small airway destruction and marked airway cellular inflammation, which result in prominent expiratory airflow limitation, air trapping, hyperinflation and abnormal gas exchange. COPD is strongly linked with the exposition to inhaled irritants, most notably tobacco smoke, and is as such a potentially preventable disease. COPD-related morbidity, mortality and social costs are high: in Canada, COPD is the main cause of hospital admission among all chronic diseases and is the fourth leading cause of death. Diagnosis of COPD requires the objective demonstration of expiratory airflow limitation using spirometry. In the right clinical context, a post-bronchodilator forced vital capacity (FVC) / forced expiratory volume in 1 second (FEV1) ratio <0.70 is considered indicative of the presence of COPD, and therefore pulmonary function testing is required to make the diagnosis. However, the natural history of COPD represents a slowly-progressive continuum: active smokers that do not meet the criteria for COPD are still at risk of developing the disease. In fact, when compared to healthy non-smokers, active smokers without overt COPD can already show some pathological and clinical features of the disease. Notably, they report increased levels of resting dyspnea, chronic cough, lower exercise capacity, exercise-induced dynamic hyperinflation and marked airway inflammatory cellular infiltration, while conserving normal pulmonary function test values. These findings highlight the negative, clinically-measurable effects of tobacco smoking on pulmonary function, but also the limitations of standard pulmonary function testing in identifying the presence of early, mild airway disease and quantifying physiological limitations in these subjects. As such, there is a need for a novel, simple and reliable method of quantifying airway disease in this population. Quantitative lung ventilation single-photon emission computed tomography (SPECT) allows an objective quantification of the regional heterogeneity of ventilation in humans. The coefficient of variation (CV) of the distribution of a radioactive tracer, inhaled during the test, allows the generation of heterogeneity maps and density curves of small elements of the lung. These variables are sensitive to the presence of COPD, asthma, air trapping and are correlated to even slight anomalies in pulmonary function testing in otherwise healthy subjects. As such, SPECT could prove useful as an early marker of airway disease in active smokers at risk of developing COPD, but its use in this context has never been formally tested. This pilot study addresses the question of whether lung SPECT could provide clinically relevant information on airway disease in active smokers without overt lung disease on pulmonary lung function testing.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03728712
Study type Observational
Source Centre hospitalier de l'Université de Montréal (CHUM)
Contact
Status Completed
Phase
Start date January 30, 2019
Completion date November 9, 2022

See also
  Status Clinical Trial Phase
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Active, not recruiting NCT02643914 - Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings N/A
Recruiting NCT02422914 - Benefits of Tobacco Free Cigarette N/A
Active, not recruiting NCT02629679 - Sports, Education and Consumption of Substances in Adolescents N/A
Completed NCT02385227 - Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes N/A
Completed NCT02218281 - Developing a Smartphone App With Mindfulness Training for Teen Smoking Cessation N/A
Completed NCT01199380 - Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms Phase 2
Completed NCT01692353 - Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers N/A
Completed NCT01081119 - Brief Voluntary Alcohol and Drug Intervention for Middle School Youth Phase 2
Completed NCT00756704 - The Effectiveness of Smoking Cessation Guidelines in the Emergency Department N/A
Completed NCT00802919 - Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors Phase 4
Completed NCT00682474 - School Nurse-Delivered Smoking Cessation Intervention Phase 2/Phase 3
Active, not recruiting NCT05520775 - Semaglutide for Alcohol Use Disorder Phase 2
Terminated NCT03840694 - Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-world Behavior N/A
Not yet recruiting NCT06032793 - Effects of Deep Breathing Exercise on Pulmonary Function, Perceived Stress and Physical Fitness. N/A
Terminated NCT03326128 - High Dose Bupropion for Smoking Cessation - Pilot Study Phase 2
Recruiting NCT03218670 - Your Health in On Click N/A
Completed NCT02538042 - Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue) N/A
Completed NCT02792426 - Nicotine Pharmacokinetics From Research Electronic Nicotine Delivery System S-TA-U001 in Smokers and E-Cigarette Users Phase 1